Search Results
Search this site
191 results found
- Nanoparticles: Small Carriers, Big Impact
Introduction: What are nanoparticles? Nanoparticles (NPs) are particles with sizes ranging from 1 to 100 nanometers and can be categorized based on their properties, shapes, or sizes. Their nanoscale dimensions and large surface area make them possess unique physical and chemical characteristics. These attributes make NPs ideal for a wide range of applications, including enhancing catalysis, imaging, biomedical uses, energy research, and environmental technologies (Khan et al ., 2019). Examples of some naturally occurring nanoparticles are Silver (Ag), Gold (Au), Iron Oxide (Fe3O4), and Silica (SiO2). Ag can be found in aquatic environments and are used for their antimicrobial properties in products like plastics, paints, and cosmetics. Au are found in ore deposits and are utilized in tumor phototherapy, immunoassays, and biosensors. Fe3O4 are present in sediments and are employed in controlled drug release systems. SiO2, which can be released during volcanic eruptions or found naturally in rocks, sand, soil and water, are used as food additives, in cellular imaging, and as nanocarriers (Griffin et al ., 2017). NPs can be engineered to interact with biological systems at both the molecular and cellular levels. This precise interaction makes them highly promising tools for influencing and modulating the microbiome. Nanocarriers Nanocarriers (NCs) are nanoengineered, biocompatible materials or devices designed to work in combination with bioactive compounds. They play a crucial role in pharmaceutical and also in cosmetic sciences by enhancing the delivery and efficacy of therapeutic agents (Rout et al ., 2018). For instance, NCs enhance drug delivery by ensuring that antifungal medications are more effectively targeted to the infection site, improving their therapeutic impact. Their small size allows for better skin penetration as well as a controlled and sustained release of drugs, which maintains therapeutic levels longer and reduces the frequency of application. Additionally, nanocarriers improve the bioavailability of poorly soluble drugs and minimize systemic side effects by focusing the drug action more precisely on the infected areas (Keshwania et al ., 2023). Bioconjugated nanoparticulate systems are now being employed in the treatment of a range of severe and previously incurable infectious diseases, including tuberculosis, as well as chronic conditions like diabetes and various types of cancers (Rout et al ., 2018). Challenges in modulating the skin microbiome Rising Antimicrobial Resistance A significant challenge in skin microbiome management is the development of antimicrobial resistance. For instance, many Cutibacterium acnes strains, a common skin bacterium associated with acne, have developed resistance to major antibiotics such as erythromycin, clindamycin, doxycycline, trimethoprim/sulfamethoxazole, and tetracycline (Alkhawaja et al ., 2020). Stability and Competition of Applied Microbiota Stabilizing applied bacteria on the skin is challenging. Despite initial topical disinfection, it is difficult to eliminate the existing subcutaneous microbiota. Consequently, new microbiota applied to the skin surface must compete with the microbiota residing in deeper skin layers, which can undermine their effectiveness (Callewaert et al ., 2021). Technical Difficulties in Probiotic Delivery Delivering probiotics effectively presents its own set of challenges: limited concentrations, low viability in harsh environments, susceptibility to oxidative damage, challenging preservation and distribution, etc. Encapsulation technology offers a solution by enabling precise and controlled release of probiotics at varying concentrations. This method protects probiotics from harsh conditions and environmental factors such as oxygen, temperature, and light, enhancing their survival and functionality (Pandey et al ., 2024). Advances of nanotechnology in biomedical applications To address these challenges nanotechnology has been advancing rapidly, particularly in the development of innovative drug delivery systems. Innovations in nanocarrier systems, such as nanoparticles and liposomes (Figure 1), are now engineered to specifically target pathogens or infected tissues (Zong et al ., 2022). Liposomes can carry both water-soluble (Figure 1a) and fat-soluble (Figure 1b) drugs in one structure. They are biocompatible, biodegradable, low in toxicity, and cause minimal immune response. Different types of liposomes can be made positively charged, negatively charged, or neutral (Figure 1c). Liposomes interact with cells mainly through endocytosis (Figure 1d) or fusion (Figure 1e). Additionally, they can easily be modified with surface appendages allowing them to target molecules like antibodies, proteins, or enzymes to direct drugs to infection sites (Figure 1f) (Zong et al ., 2022). NP as Transdermal drug delivery systems (TDDS) The transdermal drug delivery system is a technique that allows drugs to be absorbed through the skin. Nevertheless, the great hydrophobicity and physiology of the skin layers prevent the passive permeation of drug molecules over 500kDA, thus limiting transdermal drug diffusion. Nanoparticles have the ability to improve drug bioavailability, drug penetration and physical stability alongside providing precise dose control and targeted delivery, ensuring that drugs are released in a controlled manner and directed specifically to desired tissues or skin layers. This improved targeting helps in overcoming the skin barrier, thus enhancing treatment efficacy and reducing side effects (Palmer & DeLouise., 2016). Drugs can penetrate the stratum corneum (SC) through two primary pathways: the transepidermal route and the transappendageal route (Figure 2). Transepidermal route In the transepidermal route, drugs can penetrate the skin via two pathways: the transcellular route , which is a direct path through corneocytes and lipid layers, and the intercellular route , which involves diffusing through the lipid matrix around corneocytes. Hydrophilic drugs typically use the transcellular route, while lipophilic drugs prefer the intercellular route (Barnes et al ., 2021). While lipophilic and amphiphilic molecules favour the intercellular route, the architecture of the epidermis presents a difficult path to follow causing limited permissibility. However, skin penetration enhancers (e.g. DMSO, glycols, laurocapram, etc.) can enhance drug permeation. The transcellular pathway on the other hand would be unfavorable for most drugs as they would be required to alternate hydrophilic and lipophilic regions. Transappendagel route The transappendageal route involves drug transport through sweat glands and hair follicles, creating channels across the SC. While these appendages cover only about 0.1% of the skin's surface and contribute minimally to drug absorption, they are crucial for ions and large polar molecules. Sweat ducts and sebaceous glands can limit drug permeation due to their hydrophilic and lipid-rich environments (Barnes et al ., 2021). Notwithstanding, they benefit from accelerated transport through the skin and can serve as a reservoir for the drugs for an improved and sustained controlled localised release into skin in addition to a great proximity to the capillary vessels, facilitating systemic delivery. How can nanoparticles be used to modulate the microbiome? Nanocarriers as delivery systems Delivery of antimicrobial agents NPs can be engineered to carry antimicrobial agents like antibiotics, antimicrobial peptides, or essential oils, delivering them directly to targeted areas of the skin to combat harmful microbes. For instance, silver nanoparticles are known for their broad-spectrum antimicrobial properties, effectively inhibiting the growth of various bacteria and fungi. This makes them valuable in treating skin infections, as they can disrupt microbial cell membranes, inhibit enzyme activity, and generate reactive oxygen species (ROS) that lead to microbial death (Yin et al ., 2020). Assisting probiotic delivery Encapsulating probiotics within protective nanocarriers acts as a physical barrier that shields them from harsh environments, such as stomach acid and bile, ensuring higher survival rates upon consumption. This encapsulation also protects probiotics from external factors like temperature and light during storage, enhancing their stability and shelf life. Additionally, nanocarriers enable the precise and controlled release of probiotics at targeted sites, maximizing their therapeutic potential. Co-encapsulation is also an option, where probiotics and other bioactive compounds are delivered together, potentially enhancing overall health benefits through synergistic effects (Pandey et al ., 2024). Targeted drug delivery NPs can be engineered for specific cell, tissue, or location targeting by modifying their surface with ligands or antibodies, allowing for precise delivery of therapeutic agents directly to the intended site. This targeted approach significantly limits off-target effects, reducing damage to healthy cells and minimizing bystander effects. Additionally, the enhanced targeting and delivery efficiency provided by NPs enable a reduction in the required dose of the therapeutic compound, improving safety, and conserving biocompounds (Afzal et al ., 2021). Hussain et al. (2018) accomplished this by conjugating a 9 amino acid oligopeptide to a porous silicon NP loaded with antibiotic targeting specifically S. aureus infected tissues. Disruption of biofilms A biofilm is a collection of microbial cells attached to a surface, encased in a matrix of extracellular polymeric substances (Donlan et al ., 2002). Following are few metal NPs that are known to have strong defence mechanism to combat biofilm formation; Immunomodulation There are four types of immunomodulatory nanosystems: organic , inorganic , biomimetic , and naturally derived . Organic nanosystems, such as liposomes and polymeric nanoparticles, are known for their biocompatibility and controlled release capabilities. Inorganic nanosystems, including metal and silica nanoparticles, offer stability and can directly interact with immune cells. Biomimetic nanosystems mimic natural biological structures, enhancing cellular uptake and immune response. Naturally derived nanosystems use compounds from natural sources, like plant extracts or microbial products, providing inherent biocompatibility and immunomodulatory properties (Khatun et al ., 2023). Case study: Probiotic-based nanoparticles for targeted microbiota modulation and immune restoration in bacterial pneumonia (Fu et al ., 2022) Fu et al. designed probiotic-based nanoparticles called OASCLR by coating chitosan (CS), hyaluronic acid (HA), and ononin onto living Lactobacillus rhamnosus (LR). This probiotic was chosen by virtue of its microbial competitiveness, its ability to modulate the immune response in hyperactive immunocompetent and immunocompromised hosts and its role as a modulator of the microbiome composition. To ensure the viability of LR in the lungs, the probiotic was first encapsulated in CS, known for its unique mucoadhesive properties and great biocompatibility. HA was then added as it can regulate the immune system by specifically targeting pro-inflammatory M1 macrophages via CD44 receptors. To alleviate the oxidative damage rising from the harsh conditions in the lungs, the isoflavone Ononin was added to the coating. Through ROS-scavenging, anti-inflammatory and anti-oxidant properties, ononin could enhance OASCLR’s resistance against ROS-mediated cytotoxicity and hyaluronidase degradation while also promoting the growth of LR and inhibiting pathogens. Considering the low bioactivity of LR in the ROS environment, the designed CS/HA–ononin shell could prevent LR from oxygen damage and allow OASCLR nanoparticles targeting pro-inflammatory macrophages by the interaction of HA with CD44. These nanoparticles demonstrated over 99.97% antibacterial efficiency against common clinical pathogens. Notably, OASCLR modulated lung microbiota by reducing pathogens and enhancing the richness and diversity of probiotic and commensal bacteria. They also targeted inflammatory macrophages via CD44, alleviating excessive immune responses in hyperactive pneumonia. Additionally, OASCLR improved macrophage phagocytic function in immunocompromised pneumonia, increasing phagocytic ability from 2.61% to 12.3%. This work suggests a promising strategy for treating both hyperactive and immunocompromised bacterial pneumonia (Figure 3) (Fu et al ., 2022). Method To determine whether the lung microbiome was altered following OASCLR treatment, the study established a primary pneumonia model in mice using Staphylococcus aureus (SA). The experimental design involved infecting mice with SA via nasal intubation on Day -3. The mice were then treated with either PBS as a negative control or OASCLR through non-invasive aerosol inhalation on Day 0. Blood tests were conducted on Days 1 and 7, and 16S ribosomal RNA gene sequencing was performed on Day 2 to analyze changes in the lung microbiome (Figure 4) (Fu et al ., 2022). Results: Modulation of lung microbiome by OASCLR OASCLR group exhibited a higher Chao richness index, indicating greater bacterial species richness (Figure 5D). Further analysis showed a shift in microbiota composition, with increased Firmicutes and decreased Proteobacteria and Bacteroidota (Figure 5E). Additionally, OASCLR reduced pathogenic bacteria like Staphylococcus while boosting probiotic and commensal bacteria such as Lactobacillus and Bifidobacterium , suggesting that OASCLR effectively promotes a healthier lung microbiota (Figure 5F) (Fu et al ., 2022). Results: Decreased inflammation Immunofluorescence analysis revealed that OASCLR treatment reduced CD45 and TNF-α expression while slightly increasing IL-10, indicating a decrease in pro-inflammatory responses. RT-PCR analysis also showed a decreased TNF-α to IL-10 ratio in the OASCLR group compared to PBS (Figure 6). These results suggest that OASCLR effectively modulates excessive inflammation in primary bacterial pneumonia (Fu et al ., 2022). Results: Macrophage polarization OASCLR treatment altered the immune landscape by reducing pro-inflammatory markers such as TNF-α and increasing anti-inflammatory IL-10. It also lowered the expression of CD80, a marker associated with M1 macrophages, which are typically involved in pro-inflammatory responses and tissue damage. They suggested that (This indicates that) OASCLR promotes a shift towards M2 macrophages, which are known for their anti-inflammatory properties, enhanced phagocytosis, and role in tissue repair and regeneration. This change in macrophage polarisation suggests that OASCLR helps reduce inflammation and supports tissue healing (Fu et al ., 2022). Results: Biocompatibility The mice treated with OASCLR showed no significant tissue damage or adverse effects. Blood tests and H&E staining confirmed that OASCLR nanoparticles did not affect liver or kidney function and were safe for major organs. These findings suggest OASCLR has strong therapeutic potential for treating hyperactive immunocompetent primary pneumonia while complying to biocompatibility requirements (Fu et al ., 2022). Conclusion of the case study OASCLR nanoparticles were reported to restore host immunity, regulate lung inflammation, and enhance macrophage phagocytosis in bacterial pneumonia. The ononin shell allows immune evasion and safe clearance, supporting clinical use. Combining probiotics with biomaterials boosts their function, making OASCLR nanoparticles a potential treatment for various diseases beyond pneumonia (Fu et al ., 2022). Consideration of NPs for microbiome modulation Challenges in using NPs for microbiome modulation include meeting strict regulatory standards, achieving precise targeting to avoid off-target effects, and ensuring NPs stability during storage and administration. It is also important to understand the NPs degradation to ensure timely and effective drug release. These factors are critical for advancing NP-based therapies in clinical settings (Wang et al ., 2017). Conclusion: Small entities for a big future NPs have a potential to significantly impact antimicrobial therapy and microbiome modulation despite their tiny size. NPs' unique properties, such as their ability to target specific pathogens and modulate biological systems, position them as powerful tools for advancing medical treatments. This perspective underscores the transformative possibilities of NPs in addressing current challenges in healthcare, including antibiotic resistance and precise drug delivery (Wang et al ., 2017). References Afzal Shah, Saima Aftab, Jan Nisar, Muhammad Naeem Ashiq, Faiza Jan Iftikhar, Nanocarriers for targeted drug delivery, Journal of Drug Delivery Science and Technology, Volume 62, 2021, 102426, ISSN 1773-2247, https://doi.org/10.1016/j.jddst.2021.102426 . ( https://www.sciencedirect.com/science/article/pii/S1773224721001064 ) Ali SG, Ansari MA, Alzohairy MA, Alomary MN, AlYahya S, Jalal M, Khan HM, Asiri SMM, Ahmad W, Mahdi AA, El-Sherbeeny AM, El-Meligy MA. Biogenic Gold Nanoparticles as Potent Antibacterial and Antibiofilm Nano-Antibiotics against Pseudomonas aeruginosa . Antibiotics (Basel). 2020 Feb 27;9(3):100. doi: 10.3390/antibiotics9030100. PMID: 32120845; PMCID: PMC7148532. Alkhawaja E, Hammadi S, Abdelmalek M, Mahasneh N, Alkhawaja B, Abdelmalek SM. Antibiotic resistant Cutibacterium acnes among acne patients in Jordan: a cross sectional study. BMC Dermatol. 2020 Nov 17;20(1):17. doi: 10.1186/s12895-020-00108-9. PMID: 33203374; PMCID: PMC7673087. Barnes TM, Mijaljica D, Townley JP, Spada F, Harrison IP. Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison. Pharmaceutics. 2021 Nov 26;13(12):2012. doi: 10.3390/pharmaceutics13122012. PMID: 34959294; PMCID: PMC8703425. Callewaert C, Knödlseder N, Karoglan A, Güell M, Paetzold B. Skin microbiome transplantation and manipulation: Current state of the art. Comput Struct Biotechnol J. 2021 Jan 4;19:624-631. doi: 10.1016/j.csbj.2021.01.001. PMID: 33510866; PMCID: PMC7806958. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002 Sep;8(9):881-90. doi: 10.3201/eid0809.020063. PMID: 12194761; PMCID: PMC2732559. Fu J, Liu X, Cui Z, Zheng Y, Jiang H, Zhang Y, Li Z, Liang Y, Zhu S, Chu PK, Yeung KWK, Wu S. Probiotic-based nanoparticles for targeted microbiota modulation and immune restoration in bacterial pneumonia. Natl Sci Rev. 2022 Oct 16;10(2):nwac221. doi: 10.1093/nsr/nwac221. PMID: 36817841; PMCID: PMC9935993. Griffin S, Masood MI, Nasim MJ, Sarfraz M, Ebokaiwe AP, Schäfer KH, Keck CM, Jacob C. Natural Nanoparticles: A Particular Matter Inspired by Nature. Antioxidants (Basel). 2017 Dec 29;7(1):3. doi: 10.3390/antiox7010003. PMID: 29286304; PMCID: PMC5789313. Hussain, S., Joo, J., Kang, J., Kim, B., Braun, G.B., She, Z.-G., Kim, D., Mann, A.P., Mölder, T., Teesalu, T., Carnazza, S., Guglielmino, S., Sailor, M.J., Ruoslahti, E., 2018. Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy. Nat Biomed Eng 2, 95–103. https://doi.org/10.1038/s41551-017-0187-5 Ingle AP, Duran N, Rai M. Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: a review. Appl Microbiol Biotechnol. 2014 Feb;98(3):1001-9. doi: 10.1007/s00253-013-5422-8. Epub 2013 Dec 5. PMID: 24305741. Jardeleza C, Rao S, Thierry B, Gajjar P, Vreugde S, Prestidge CA, Wormald PJ. Liposome-encapsulated ISMN: a novel nitric oxide-based therapeutic agent against Staphylococcus aureus biofilms. PLoS One. 2014 Mar 21;9(3):e92117. doi: 10.1371/journal.pone.0092117. PMID: 24658315; PMCID: PMC3962386. Keshwania P, Kaur N, Chauhan J, Sharma G, Afzal O, Alfawaz Altamimi AS, Almalki WH. Superficial Dermatophytosis across the World's Populations: Potential Benefits from Nanocarrier-Based Therapies and Rising Challenges. ACS Omega. 2023 Aug 22;8(35):31575-31599. doi: 10.1021/acsomega.3c01988. PMID: 37692246; PMCID: PMC10483660. Khan, Ibrahim & Saeed, Khalid & Khan, Idrees. (2019). Nanoparticles: Properties, Applications and Toxicities. Arabian Journal of Chemistry. 12. 908-931. 10.1016/j.arabjc.2017.05.011. Khatun S, Putta CL, Hak A, Rengan AK. Immunomodulatory nanosystems: An emerging strategy to combat viral infections. Biomater Biosyst. 2023 Jan 30;9:100073. doi: 10.1016/j.bbiosy.2023.100073. PMID: 36967725; PMCID: PMC10036237. Palmer BC, DeLouise LA. Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting. Molecules. 2016 Dec 15;21(12):1719. doi: 10.3390/molecules21121719. PMID: 27983701; PMCID: PMC5639878. Pandey, R.P., Gunjan, Himanshu et al. Nanocarrier-mediated probiotic delivery: a systematic meta-analysis assessing the biological effects. Sci Rep 14, 631 (2024). https://doi.org/10.1038/s41598-023-50972-x Rout GK, Shin HS, Gouda S, Sahoo S, Das G, Fraceto LF, Patra JK. Current advances in nanocarriers for biomedical research and their applications. Artif Cells Nanomed Biotechnol. 2018;46(sup2):1053-1062. doi: 10.1080/21691401.2018.1478843. Epub 2018 Jun 7. PMID: 29879850. Trivedi R, Upadhyay TK, Kausar MA, Saeed A, Sharangi AB, Almatroudi A, Alabdallah NM, Saeed M, Aqil F. Nanotechnological interventions of the microbiome as a next-generation antimicrobial therapy. Sci Total Environ. 2022 Aug 10;833:155085. doi: 10.1016/j.scitotenv.2022.155085. Epub 2022 Apr 6. PMID: 35398124. Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int J Nanomedicine. 2017 Feb 14;12:1227-1249. doi: 10.2147/IJN.S121956. PMID: 28243086; PMCID: PMC5317269. Yin IX, Zhang J, Zhao IS, Mei ML, Li Q, Chu CH. The Antibacterial Mechanism of Silver Nanoparticles and Its Application in Dentistry. Int J Nanomedicine. 2020 Apr 17;15:2555-2562. doi: 10.2147/IJN.S246764. PMID: 32368040; PMCID: PMC7174845. Zong TX, Silveira AP, Morais JAV, Sampaio MC, Muehlmann LA, Zhang J, Jiang CS, Liu SK. Recent Advances in Antimicrobial Nano-Drug Delivery Systems. Nanomaterials (Basel). 2022 May 29;12(11):1855. doi: 10.3390/nano12111855. PMID: 35683711; PMCID: PMC9182179.
- Wound Wonders: Innovation in the Microbiome Space for Burn Healing
In the UK, around 120,000 people visit A&E annually due to burn injuries, with 72% resulting in hypertrophic scarring, a type of raised scar that forms within the boundaries of the original wound due to excessive collagen production during healing. While traditional wound dressings effectively promote healing, there’s growing interest in innovative approaches that address post-burn scarring more effectively. What We Know: Traditional dressings help close and heal wounds by providing hydration and antimicrobial protection, but they aren’t designed to prevent or treat post-burn scarring. Burns disrupt the skin’s microbial balance, favouring heat-loving microbes like Aeribacillus, Caldalkalibacillus and Nesterenkonia while reducing beneficial bacteria such as Cutibacterium, Staphylococci and Corynebacteria . Increased levels of Corynebacterium are linked to higher infection risks, whereas Staphylococci and Cutibacterium are associated with lower infection rates post-burn (Yang et al., 2024). Despite reduced bacterial richness at the genus level, burn patients exhibit increased microbial community diversity and evenness. This altered microbial landscape, marked by a lower overall bacterial burden and an overgrowth of Staphylococcus species, highlights a persistent dysbiotic state in the skin microbiota during the subacute phase of wound healing (Liu et al., 2018) . Industry Impact and Potential: @Healome Therapeutics has developed a groundbreaking bioactive skin dressing technology, recently cleared by the @Medicines and Healthcare products Regulatory Agency (MHRA) for a phase I trial aimed at reducing scarring. The trial, conducted at Queen Elizabeth Hospital in Birmingham, UK, involves 25 patients with burns covering 3-20% of their body surface. Healome’s innovative dressing is a clear film that not only offers the benefits of traditional wound dressings but also incorporates synthetic human-derived decorin protein, which plays a critical role in wound healing. This protein reduces the inflammatory response and regulates the wound’s microenvironment. Early research suggests that this approach may reduce fibrosis and promote tissue regeneration, offering new hope for scar management in burn patients. Products like Healome’s dressing showcase the exciting potential of using the microbiome and skin environment to enhance wound healing, paving the way for future innovations in burn care. Our Solution: At Sequential, we offer comprehensive services for evaluating product impacts and formulations, supported by a vast database of over 20,000 microbiome samples and 4,000 ingredients, along with a global network of more than 10,000 testing participants. Our customizable microbiome studies simulate real-world testing scenarios, ensuring that your products preserve biome integrity while delivering optimal results. References: Liu, S.-H., Huang, Y.-C., Chen, L.Y., Yu, S.-C., Yu, H.-Y. & Chuang, S.-S. (2018) The skin microbiome of wound scars and unaffected skin in patients with moderate to severe burns in the subacute phase. Wound Repair and Regeneration: Official Publication of the Wound Healing Society [and] the European Tissue Repair Society. 26 (2), 182–191. doi:10.1111/wrr.12632. Yang, Y., Huang, J., Zeng, A., Long, X., Yu, N. & Wang, X. (2024) The role of the skin microbiome in wound healing. Burns & Trauma. 12, tkad059. doi:10.1093/burnst/tkad059.
- Is Swimming Wrecking Your Skin Microbiome?
Swimming is a widely enjoyed physical activity that provides various health benefits, such as improved cardiovascular fitness, enhanced muscle strength, and reduced stress levels. Nevertheless, swimming also involves exposure to different water environments, including chlorinated pools, seawater, and freshwater lakes. Each of these environments possesses distinct chemical and microbial properties that can uniquely affect the skin microbiome. Consequently, comprehending the significance of the skin microbiome in swimming is essential. What we know: Studies have found that exposure to chlorinated pool water reduces microbial diversity on the skin, as it acts as a disinfectant, killing both harmful and beneficial bacteria, which can lead to an imbalance in the skin microbiome. This imbalance may increase the risk of skin conditions like dermatitis and infections (Puce et al ., 2022). Ocean water contains a diverse range of marine bacteria, thereby enhancing the diversity of the skin microbiome. The ocean water simultaneously removes resident skin bacteria while depositing ocean-borne bacteria onto the skin (Nielsen et al ., 2019). The predominating phyla Actinobacteria , Firmicutes , and Proteobacteria on the skin changed after swimming when compared to before swimming tends to decrease, whereas Bacteroidetes tends to increase. As time passed, the bacterial community composition trended towards baseline (Nielsen et al ., 2019). The quantity of Vibrio spp. found on human skin was over ten times higher than that in the ocean water sample (which was only 0.032%), indicating that Vibrio spp. has a particular affinity for adhering to human skin (Nielsen et al ., 2019). Industry impact & potential: Research shows that males are more prone to acquiring infections from Vibrio vulnificus and Aeromonas spp. following water exposure. Future research could provide valuable insights into the factors contributing to these infections and explore potential differences in the skin microbiome between males and females after such exposure (Nielsen et al ., 2019). Formulations such as post and pre-swim cleansers and moisturizers should be designed to aid in microbiome recovery while also protecting the skin from chlorine and salt damage. Our solution: Sequential, is a company focusing on microbiome studies. We carry out various services from clinical testing to helping with formulations. We have at home testing kits that will allow you to discover the state of your skin microbiome. Through our Skin Health Tracker app, we can give you tips on how you can improve your skin and the microbiome. Reference: Nielsen MC, Jiang SC. Alterations of the human skin microbiome after ocean water exposure. Mar Pollut Bull. 2019 Aug;145:595-603. doi: 10.1016/j.marpolbul.2019.06.047. Epub 2019 Jul 2. PMID: 31590829; PMCID: PMC8061468. Puce L, Hampton-Marcell J, Trabelsi K, Ammar A, Chtourou H, Boulares A, Marinelli L, Mori L, Cotellessa F, Currà A, Trompetto C, Bragazzi NL. Swimming and the human microbiome at the intersection of sports, clinical, and environmental sciences: A scoping review of the literature. Front Microbiol. 2022 Aug 3;13:984867. doi: 10.3389/fmicb.2022.984867. PMID: 35992695; PMCID: PMC9382026.
- Exploring the Impact of The Scalp Microbiome on Alopecia Treatments: New Insights and Innovations
The scalp microbiome plays a crucial yet often overlooked role in the development and treatment of alopecia. Studies have shed light on how rebalancing these microbes can significantly enhance the efficacy of treatments for hair loss, offering new hope for patients. What We Know: Cutibacterium spp. and Staphylococcus spp . constitute about 90% of healthy scalp microbiomes, with Corynebacterium spp., Streptococcus spp., Acinetobacter spp . and Prevotella spp . making up the remaining 10% (Jo et al., 2022) . Alopecia patients’ scalp microbiomes exhibit increased C. acnes , Stenotrophomonas geniculata, Wallemia and Eurotium , as well as reduced Malassezia, when compared to healthy individuals. Therefore, it is likely that an imbalance in scalp microbiota may contribute to alopecia (Zhang et al., 2024) . Industry Impact and Potential: Platelet-rich plasma (PRP) has proven effective in treating alopecia, but its impact on the scalp microbiome was previously unexplored. A recent study revealed that PRP treatment rebalances the scalp microbiome, specifically increasing Cutibacterium levels while decreasing Staphylococcus and Lawsonella levels (Zhang et al., 2024) . Cutibacterium plays a vital role in maintaining skin homeostasis and is crucial for lipid regulation, follicular niche competition, immune regulation and mitigating oxidative stress. Furthermore, the balance between Cutibacterium and Staphylococcus is important for regulating immune response. Reduction in Lawsonella suggests decreased scalp sebum production following treatment. This is relevant to alopecia treatment, as imbalances in sebum production can exacerbate hair loss by contributing to inflammation and follicle damage (Zhang et al., 2024) . Lactic acid bacteria (LAB), Limosilactobacillus fermentum LM1020 and its heat-treated version HT-LM1020, can help promote hair growth on human scalp tissue and dermal papilla cells. These bacteria work with other ingredients to fight hair loss by boosting cell growth and regulating the expression of proteins important for cell division (Bae et al., 2024) . AMOREPACIFIC patented a composition that uses extracellular follicles derived from LAB to prevent hair loss, stimulate hair growth and support overall hair health. These extracellular follicles (cellular components or secretions released by the bacteria) represent a promising advancement in alopecia treatment, offering potential benefits for both hair and scalp health. Our Solution: With a database of over 20,000 microbiome samples and 4,000 ingredients, and a global network of more than 10,000 testing participants, Sequential offers comprehensive services to evaluate product impacts and formulations. Our customisable microbiome studies provide real-life context testing, and our formulation support ensures products maintain biome integrity, making us the ideal partner for your product development and efficacy needs. References: Bae, W.-Y., Jung, W.-H., Shin, S.L., Kim, T.-R., Sohn, M., Suk, J., Jung, I., Lee, Y.I. & Lee, J.H. (2024) Heat-treated Limosilactobacillus fermentum LM1020 with menthol, salicylic acid, and panthenol promotes hair growth and regulates hair scalp microbiome balance in androgenetic alopecia: A double-blind, randomized and placebo-controlled clinical trial. Journal of Cosmetic Dermatology . n/a (n/a). doi:10.1111/jocd.16357. Jo, H., Kim, S.Y., Kang, B.H., Baek, C., Kwon, J.E., Jeang, J.W., Heo, Y.M., Kim, H.-B., Heo, C.Y., Kang, S.M., Shin, B.H., Nam, D.Y., Lee, Y.-G., Kang, S.C. & Lee, D.-G. (2022) Staphylococcus epidermidis Cicaria, a Novel Strain Derived from the Human Microbiome, and Its Efficacy as a Treatment for Hair Loss. Molecules . 27 (16). doi:10.3390/molecules27165136. Zhang, Q., Wang, Y., Ran, C., Zhou, Y., Zhao, Z., Xu, T., Hou, H. & Lu, Y. (2024) Characterization of distinct microbiota associated with androgenetic alopecia patients treated and untreated with platelet‐rich plasma (PRP). Animal Models and Experimental Medicine . 7 (2), 106–113. doi:10.1002/ame2.12414.
- Diabetes Dilemma: The Skin Microbiome’s Influence on Diabetic Skin and Wound Healing
Diabetes mellitus is a chronic condition marked by elevated blood glucose levels due to abnormal insulin production or insulin resistance, leading to complications of the heart, kidneys, eyes, blood vessels and nerves. Type 2 diabetes specifically is associated with skin issues like chronic foot ulcers and increased infections, potentially due to disruptions in the skin microbiome. What We Know: In 2021, the global prevalence of diabetes among adults was estimated at 537 million and is projected to rise to 783 million by 2045 (International Diabetes Federation, 2021). Diabetic foot ulcers (DFUs) are defined as “Ulcers in the foot of individuals with diabetes, often accompanied by lower limb neuropathy and/or peripheral arterial disease.” DFU can also be defined as a chronic skin disease linked to altered bacterial diversity and instability in wound microbiota (Zhang et al., 2023). The total lifetime risk of DFU complications for patients with diabetes (type 1 or 2) is 25%. These wounds are slow to heal, difficult to treat and vulnerable to infection (Gardiner et al., 2017; Packer, Ali & Manna, 2024). Bacterial infection is the most common cause of delayed healing in DFUs and the lack of appropriate diagnostic tools makes it difficult to determine if the bacteria in the DFU are due to changes in the original colonised bacteria or an external infection. Few studies have investigated the transition of bacterial flora from healthy skin to diabetic skin to DFU skin (Zhang et al., 2023). Industry Impact and Potential: While some bacterial species can hinder wound healing and lead to chronic wounds, others can accelerate healing and prevent pathogen colonisation. Significant differences in skin microbial composition exist between diabetic and non-diabetic patients, with diabetic wounds showing increased levels of Staphylococcus, Aerococcus, Porphyromonadaceae and Proteobacteria , and decreased levels of Streptococcus, Lachnospiraceae and Acinetobacter (Zhang et al., 2023). There are changes in the bacterial colony structure of DFU skin compared to healthy or diabetic skin without ulcers. In DFU skin, Staphylococcus , Enhydrobacter and Corynebacterium_1 are significantly reduced, while Escherichia coli and Pseudomonas are increased (Zhang et al., 2023). Thus, the difference between healthy skin and diabetic skin with or without ulcers lies in the balance between normal and pathogenic microbiota. Subsequently, altering the microbiota composition of wounds may help the treatment of DFU (Zhang et al., 2023). Our Solution: Sequential offers customisable end-to-end Microbiome Testing for your research needs, like investigating the influence of the skin microbiome on diabetic skin and wound healing. Sequential offers real-world testing scenarios, and additionally formulation support to develop products that maintain microbiome stability for the skin, as well as for the oral, scalp and vaginal microbiomes. References: Gardiner, M., Vicaretti, M., Sparks, J., Bansal, S., Bush, S., Liu, M., Darling, A., Harry, E. & Burke, C.M. (2017) A longitudinal study of the diabetic skin and wound microbiome. PeerJ. 5, e3543. doi:10.7717/peerj.3543. International Diabetes Federation (2021) IDF Diabetes Atlas. 2021. IDF Diabetes Atlas. https://diabetesatlas.org/ [Accessed: 5 July 2024]. Packer, C.F., Ali, S.A. & Manna, B. (2024) Diabetic Ulcer. In: StatPearls. Treasure Island (FL), StatPearls Publishing. p. http://www.ncbi.nlm.nih.gov/books/NBK499887/ . Zhang, X.-N., Wu, C.-Y., Wu, Z.-W., Xu, L.-X., Jiang, F.-T. & Chen, H.-W. (2023) Association Between the Diabetic Foot Ulcer and the Bacterial Colony of the Skin Based on 16S rRNA Gene Sequencing: An Observational Study. Clinical, Cosmetic and Investigational Dermatology. 16, 2801–2812. doi:10.2147/CCID.S425922.
- Is Micro-Botox Disrupting the Skin's Microbiome Balance?
Micro-Botox is a specialised technique involving the injecting of diluted botulinum toxin into the skin. It is a frequently performed procedure to improve facial skin tone, texture, fine wrinkles, and enlarged pores. Unlike traditional Botox, which targets deeper facial muscles, Micro-Botox is administered more superficially and in a more diluted form. This allows for a more uniform and subtle rejuvenation effect without significantly affecting facial expressions. What we know: ▫️Botulinum toxin type A (BoNT-A) is widely recognized for its use as a neuromodulator in treating facial lines, correcting facial asymmetry, and creating a lifting effect in the lower face by administering via multiple injections into the superficial fibres of facial muscles ( Fabi , et al., 2023). ▫️Micro-botox has demonstrated effectiveness in enhancing the skin's sheen and texture, reducing sweat and sebum production, and minimising enlarged pores. It works by shrinking sebaceous glands, which in turn tightens the skin envelope (Salem et al., 2023). ▫️Sebum provides a nutrient-rich environment for Cutibacterium acnes. By reducing sebum production, Micro-botox can decrease the availability of nutrients for Cutibacterium acnes bacteria, potentially reducing their population (Rho et al., 2021). ▫️The combined use of Micro-Botox and hyaluronic acid has been found to enhance skin hydration and improve the dermal barrier function ( Kim , 2021). ▫️Micro-Botox is effective for facial rejuvenation, lifting the mid to lower face, and reducing fine wrinkles in the forehead and cheek areas, particularly in younger individuals. It also works for neck rejuvenation, especially in older individuals ( Iranmanesh et al., 2022). Industry impact & potential: ▫️The demand for Micro-Botox procedures continues to increase, driven by its effectiveness in addressing various skin concerns. ▫️There's potential for combining Micro-Botox with other skincare to enhance overall skin health and appearance. ▫️There is very little research that has been done on Micro-Botox and its impact on the skin microbiome. Hence, further research is needed to understand how Micro-Botox procedures impact the skin microbiome. Our solution: Sequential, specialises in microbiome analysis and we use advanced testing technologies and longitudinal study designs, to analyse changes in microbial diversity and composition pre and post treatments. By correlating these microbiome shifts with clinical outcomes such as improvements in skin texture or pore size, we aim to uncover new insights into the cosmetic procedure's impact on skin health at a microbial level. Reference: Fabi SG, Park JY, Goldie K, Wu W. Microtoxin for Improving Pore Size, Skin Laxity, Sebum Control, and Scars: A Roundtable on Integrating Intradermal Botulinum Toxin Type A Microdoses Into Clinical Practice. Aesthet Surg J. 2023 Aug 17;43(9):1015-1024. doi: 10.1093/asj/sjad044. PMID: 36857534; PMCID: PMC10481112. Iranmanesh B, Khalili M, Mohammadi S, Amiri R, Aflatoonian M. Employing microbotox technique for facial rejuvenation and face-lift. J Cosmet Dermatol. 2022 Oct;21(10):4160-4170. doi: 10.1111/jocd.14768. Epub 2022 Jan 22. PMID: 35064633. Kim JS. Fine Wrinkle Treatment and Hydration on the Facial Dermis Using HydroToxin Mixture of MicroBotox and MicroHyaluronic Acid. Aesthet Surg J. 2021 May 18;41(6):NP538-NP549. doi: 10.1093/asj/sjaa231. PMID: 32779694; PMCID: PMC8240748. Rho NK, Gil YC. Botulinum Neurotoxin Type A in the Treatment of Facial Seborrhea and Acne: Evidence and a Proposed Mechanism. Toxins (Basel). 2021 Nov 19;13(11):817. doi: 10.3390/toxins13110817. PMID: 34822601; PMCID: PMC8626011. Salem RM, Salah SAE, Ibrahim SE. Microbotox injection versus its topical application following microneedling in the treatment of wide facial pores: A split face comparative study. J Cosmet Dermatol. 2023 Apr;22(4):1249-1255. doi: 10.1111/jocd.15590. Epub 2023 Jan 6. PMID: 36606384.
- Could Snail Mucin Be the Secret to a Thriving Skin Microbiome?
Snail mucin is the secretion produced by various species of snails, and it has recently gained attention for its potential benefits in skincare and cosmetic applications. Emerging studies indicate that its unique composition provides intense hydration and skin regeneration and positively influences the skin's microbiome, which is the delicate ecosystem of microorganisms on the skin's surface. What we know: Snail mucin is a complex mixture of proteins, glycoproteins, and other bioactive compounds such as allantoin, glycolic acid, and antibacterial peptides, providing benefits such as moisturizing, wound healing, and anti-inflammatory effects (Zhu et al ., 2024). Snail mucin contains natural antimicrobial peptides that selectively inhibits the growth of pathogenic bacteria while promoting the growth of beneficial bacteria, thereby maintaining a balanced skin microbiome (McDermott et al ., 2021). Researchers have found that snail mucin demonstrates antibacterial effects against Pseudomonas aeruginosa and Staphylococcus aureus known to cause infections (Aflatooni et al ., 2023). Snail mucin is abundant in hyaluronic acid and glycolic acid, which improve skin hydration and barrier function (Yongeun et al ., 2022). A healthy skin barrier is essential for maintaining a stable microbiome, as it protects against external pathogens and prevents moisture loss. In-vitro studies had shown that Snail mucin had significantly improved the dermal density, skin elasticity, and wrinkles (Singh et al ., 2024). Cryptomphalus Aspersa snail mucin boosts keratinocytes and fibroblasts proliferation, migration, and adhesion protein expression, potentially aiding scar healing, and thereby promoting a stable microbiome environment (Singh et at ., 2024). Industry impact & potential: The growing demand for snail mucin products and the need for research into its potential uses are driving an expanding economic market. The increasing demand for snail mucin creates pressure on collection methods, highlighting the critical need for ethical habitats for their collection (Singh et al ., 2024). As snail mucin is an animal-derived product it can lead to sustainability concerns. Therefore, more sustainable alternatives are much needed, such as synthetic or lab-grown mucin. Our solution: Sequential, specializes in skin health solutions, features a state-of-the-art testing facility where we analyze the skin microbiome. We use advanced technology to test various skincare ingredients to better understand its impact on the skin microbiome. By conducting these tests, we aim to provide insights into the efficacy and sustainability of ingredients in skincare products. Reference: Aflatooni S, Boby A, Natarelli N, Albers S. Snails and Skin: A Systematic Review on the Effects of Snail-based Products on Skin Health. Journal of Integrative Dermatology . Published online October 31, 2023. McDermott M, Cerullo AR, Parziale J, Achrak E, Sultana S, Ferd J, Samad S, Deng W, Braunschweig AB, Holford M. Advancing Discovery of Snail Mucins Function and Application. Front Bioeng Biotechnol. 2021 Oct 11;9:734023. doi: 10.3389/fbioe.2021.734023. PMID: 34708024; PMCID: PMC8542881. Singh N, Brown AN, Gold MH. Snail extract for skin: A review of uses, projections, and limitations. J Cosmet Dermatol . 2024; 23: 1113-1121. doi: 10.1111/jocd.16269 Yongeun Kim, Woo-Jin Sim, Jeong-seok Lee, Tae-Gyu Lim, Snail mucin is a functional food ingredient for skin, Journal of Functional Foods, Volume 92, 2022, 105053, ISSN 1756-4646, https://doi.org/10.1016/j.jff.2022.105053 . Zhu K, Zhang Z, Li G, Sun J, Gu T, Ain NU, Zhang X, Li D. Extraction, structure, pharmacological activities and applications of polysaccharides and proteins isolated from snail mucus. Int J Biol Macromol. 2024 Feb;258(Pt 1):128878. doi: 10.1016/j.ijbiomac.2023.128878. Epub 2023 Dec 21. PMID: 38141709.
- Igniting Inquiry: Unravelling Smoking's Impact on the Oral Microbiome
While the harmful effects of smoking on overall health are widely recognised, its impact on the oral microbiome is still not fully understood, despite its significant health implications. This gap highlights the importance of delving deeper into the complex interplay between smoking and alterations in oral microbial communities. What We Know: Smoking unleashes toxic compounds into the oral cavity, fostering unstable bacterial growth in biofilms, elevating saliva acidity, depleting oxygen levels, altering bacterial attachment, promoting antibiotic resistance, and compromising immune responses (Mohammed et al., 2024) . Smokers exhibit distinctive oral microbiome profiles, featuring reduced bacterial diversity and specific increases in inflammation and disease-associated bacteria. Notably, smokers display lower levels of Neisseria, Porphyromonas , and Capnocytophaga , while showing higher levels of Actinomyces, Veillonella, Streptococcus , and anaerobic bacteria (Wu et al., 2016) . Research comparing cigarette and smokeless tobacco users highlights a more diverse oral bacterial community among tobacco users, characterised by higher Firmicutes and lower Proteobacteria abundance. Notably, tobacco users may harbour opportunistic pathogens like Neisseria subflava, Bulleidia moorei , and Porphyromonas endodontalis (Chattopadhyay et al., 2024) . Geographic and ethnic variations further underscore the complexity of smoking's impact on oral microbiomes. A study on an American smoking population showed reduced levels of Proteobacteria and genera involved in carbohydrate, energy, and xenobiotic metabolism, supporting the hypothesis that smoking depletes oxygen levels in the oral cavity. Meanwhile, research on a Puerto Rican smoking group showed that Proteobacteria , associated with cardiovascular and metabolic conditions, were highly enriched in smokers, as did a study on a Qatari population (Mohammed et al., 2024) . Industry Impact and Potential: While smoking's detrimental effects are widely acknowledged, further investigation into its impact on the oral microbiome is essential. Comprehensive, age-specific studies are pivotal to elucidate smoking's influence on oral microbiota and its role in disease progression (Mohammed et al., 2024) . Addressing these knowledge gaps is crucial to understanding smoking's intricate interplay with oral microbiome dysbiosis and chronic mouth diseases, laying the groundwork for more targeted prevention and treatment strategies. Preserving oral microbiome integrity is one clear path forward (Mohammed et al., 2024) . Our Solution: At Sequential, we specialise in oral microbiome analysis and product development, pioneering microbiome-friendly solutions. Leveraging our expertise, we stand poised to collaborate with your company in crafting innovative products that nurture a healthy oral microbiome and enhance microbiota diversity for consumers. References: Chattopadhyay, S., Malayil, L., Chopyk, J., Smyth, E., Kulkarni, P., Raspanti, G., Thomas, S.B., Sapkota, A., Mongodin, E.F. & Sapkota, A.R. (2024) Oral microbiome dysbiosis among cigarette smokers and smokeless tobacco users compared to non-users. Scientific Reports . 14 (1), 10394. doi:10.1038/s41598-024-60730-2. Mohammed, L.I., Zakaria, Z.Z., Benslimane, F.M. & Al-Asmakh, M. (2024) Exploring the role of oral microbiome dysbiosis in cardiometabolic syndrome and smoking. Experimental Lung Research . 50 (1), 65–84. doi:10.1080/01902148.2024.2331185. Wu, J., Peters, B.A., Dominianni, C., Zhang, Y., Pei, Z., Yang, L., Ma, Y., Purdue, M.P., Jacobs, E.J., Gapstur, S.M., Li, H., Alekseyenko, A.V., Hayes, R.B. & Ahn, J. (2016) Cigarette smoking and the oral microbiome in a large study of American adults. The ISME Journal . 10 (10), 2435–2446. doi:10.1038/ismej.2016.37.
- Don't Sweat It: How Deodorant Disrupts Your Underarm Microbiome
The underarm (axillary) microbiome plays a crucial role in body odour production. Although deodorants and fragranced cosmetic products are designed to prevent perspiration and malodour, their impact on these microbial communities has not been extensively studied. What We Know: The human armpit harbours a dense and diverse bacterial community, with recent studies revealing significant variation in armpit bacteria among individuals, more so than in other body areas. This variation is partly due to the use of personal hygiene products, especially deodorants and antiperspirants (Urban et al., 2016). Armpit bacterial communities primarily consist of Corynebacterium, Staphylococcus, Betaproteobacteria, Clostridiales, Lactobacillus, Propionibacterium and Streptococcus species. However, there is significant variability in these communities across different individuals (Urban et al., 2016). Research shows that deodorants and antiperspirants affect the diversity and composition of armpit bacterial communities. Despite these findings, more research is needed to understand the full impact of these products on human health (Chang & Wang, 2023). The high variability of armpit bacterial communities contrasts with the more stable bacterial compositions found in other skin areas, likely due to less frequent use of hygiene products there. Although this variability might be influenced by random factors or the presence of dead bacteria, studies indicate that the common armpit bacteria are among the most metabolically active and contribute significantly to body odour (Urban et al., 2016). Industry Impact and Potential: The broader health implications of antiperspirant and deodorant use are not well studied. While some have suggested a potential link between these products and breast cancer incidence or age of diagnosis, evidence supporting this association is inconsistent and not conclusive (McGrath, 2003; Hardefeldt, Edirimanne & Eslick, 2013). Nonetheless, due to these growing concerns about potential health risks and additionally the harmful effects of deodorants on the environment, researchers are seeking more sustainable alternatives (Chang & Wang, 2023). Additionally, exploring how hygiene products influence the axillary microbiome offers valuable insights into how human behaviour affects microbial communities, especially since over 90% of adults in the US use antiperspirants or deodorants regularly (Benohanian, 2001). We have been fortunate enough to work with pioneers in this field, like Arcaea - who developed their novel odour-preventative technology, based on the armpit microbiome in 2023. Our Solution: Sequential is a leading expert in comprehensive, end-to-end Microbiome Product Testing and Formulation. Our specialised and customisable services empower businesses to innovate microbiome-friendly products confidently, ensuring their effectiveness and compatibility for a healthier microbiome. Let us support your development efforts, particularly in facial, oral, scalp, and vaginal microbiome research and production formulation. References: Benohanian, A. (2001) Antiperspirants and deodorants. Clinics in Dermatology. 19 (4), 398–405. doi:10.1016/S0738-081X(01)00192-4. Chang, Y. & Wang, X. (2023) Sweat and odor in sportswear – A review. iScience. 26 (7). doi:10.1016/j.isci.2023.107067. Hardefeldt, P.J., Edirimanne, S. & Eslick, G.D. (2013) Deodorant Use and Breast Cancer Risk. Epidemiology. 24 (1), 172. doi:10.1097/EDE.0b013e3182781684. McGrath, K.G. (2003) An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving. European Journal of Cancer Prevention. 12 (6), 479. Urban, J., Fergus, D.J., Savage, A.M., Ehlers, M., Menninger, H.L., Dunn, R.R. & Horvath, J.E. (2016) The effect of habitual and experimental antiperspirant and deodorant product use on the armpit microbiome. PeerJ. 4, e1605. doi:10.7717/peerj.1605.
- Mosquitoes vs. Microbes: Can Your Skin's Secret Agents Defend Against Malaria?
Malaria remains one of the deadliest diseases of the last century, posing a significant global health challenge. Researchers are continually exploring innovative methods to treat and prevent the disease, with recent studies suggesting that the skin microbiome may play a crucial role in influencing malaria transmission and severity. What We Know: Malaria is caused by the Plasmodium parasite, which is carried by Anopheles mosquitoes, and reproduces inside a human host after a bite. Over 90 countries are affected by malaria, and although the mortality rate has decreased significantly over the last century, the disease remains a major global health challenge (Garcia, 2010). In 2022, there were still 247 million malaria cases and 619,000 deaths worldwide (World Health Organization, 2023). When selecting its blood host, the Anopheles mosquito is largely influenced by human body odour. Therefore, the skin microbiome plays a significant role in this process, as it is responsible for the composition of volatile organic compounds (VOCs), which are a major component of body odour (Verhulst et al., 2010). Skin secretions contain over 500 VOCs, including acids, alcohols, aldehydes, esters and ketones and Anopheles mosquitoes exhibbit electrophysiological and behavioural responses to several of these VOCs. Specific VOCs (butanoic acid, carbon dioxide, lactic acid and propanoic acid) have demonstrated an attractive quality for Anopheles mosquitoes. Meanwhile, other VOCs, including aldehydes (decanal, octanal, nonanal) and ketones (geranylacetone and 6-methyl-5-hepten-2-one) repelled mosquitoes (Showering et al., 2022). Industry Impact and Potential: Research found that Anopheles was attracted to microbial VOCs produced by Staphylococcus and was repelled by those produced by Corynebacterium. Abundance of the latter has been linked to increased levels of hexanoic acid in body odour, which may act as a contextual repellent (Showering et al., 2022). However, further insights into the mechanisms of attractive and repellent microbial VOCs are needed, and could pave the way for developing mosquito repellents with diverse modes of action (Showering et al., 2022). Modifying the human skin microbiome to produce fewer mosquito attractants or to generate repellents has the potential to decrease mosquito bites and prevent the spread of deadly mosquito-borne diseases (Coutinho-Abreu et al., 2023). Our Solution: At Sequential, we specialise in comprehensive Microbiome Product Testing tailored to meet your specific goals in formulating products, such as mosquito repellent. Our expertise and customised services empower businesses to innovate confidently in developing topical solutions. We facilitate microbiome studies to ensure these products are maintain the microbiome, promoting efficacy and compatibility for healthier skin. References: Coutinho-Abreu, I., Jamshidi, O., Raban, R., Atabakhsh, A., Merriman, J., Fischbach, M. & Akbari, O. (2023) Identification of human skin microbiome odorants that manipulate mosquito landing behavior. bioRxiv : the preprint server for biology. doi:10.1101/2023.08.19.553996. Garcia, L.S. (2010) Malaria. Clinics in Laboratory Medicine. 30 (1), 93–129. doi:10.1016/j.cll.2009.10.001. Showering, Martinez, J., Benavente, E., Gezan, S., Jones, R., Oke, C., Tytheridge, S., Pretorius, E., Scott, D., Allen, R., D’Alessandro, U., Lindsay, S., Armour, J., Pickett, J. & Logan, J. (2022) Skin microbiome alters attractiveness to Anopheles mosquitoes. BMC microbiology. 22 (1). doi:10.1186/s12866-022-02502-4. Verhulst, N.O., Andriessen, R., Groenhagen, U., Kiss, G.B., Schulz, S., Takken, W., Loon, J.J.A. van, Schraa, G. & Smallegange, R.C. (2010) Differential Attraction of Malaria Mosquitoes to Volatile Blends Produced by Human Skin Bacteria. PLOS ONE. 5 (12), e15829. doi:10.1371/journal.pone.0015829. World Health Organization (2023) Google-Books-ID: u6UOEQAAQBAJ. World malaria report 2023. World Health Organization.
- The Microbial Mysteries of Sensitive Skin: Unveiling the Microbiome's Role
Sensitive skin (SS), also known as cutaneous sensory syndrome, is characterised by abnormal hypersensitivity to various stimuli, leading to symptoms such as itching, irritation, redness, dryness, and sensations of tightness, stinging, and pain. While many factors contribute to SS, research is increasingly focusing on the role of the skin microbiome in this condition. What We Know: SS can affect individuals with both normal and disrupted skin barriers. Symptoms suggest the involvement of cutaneous nerve endings, which research has confirmed. Additionally, epidermal cells, sensory proteins, skin barrier disruption, and immune mechanisms may play roles. Some studies indicate that an impaired skin barrier and drier skin, associated with increased mast cell degranulation, underlie SS (Seite & Misery, 2018). Commensal bacteria reside in the epidermis, where pain and itch receptors (nociceptors and proprioceptors) are located. The skin microbiota influences mast cell movement, location, and development in the skin, and can directly stimulate pain and itch receptors. Therefore, it is suggested that bacteria may contribute to SS development, but more research is needed to fully elucidate this link (Seite & Misery, 2018). Studies have shown that the facial microbiome of individuals with SS differs from those with normal skin. Increased levels of Actinomyces, Microbotryomycetes, Dermabacter, Chryseobacterium, Rhodotorula, Peptoniphilus, Cutibacterium, Corynebacterium , and Staphylococcus were observed in SS. Notably, Dermabacter hominis was also more prevalent in the SS group, while Streptococcus strains and Acidimicrobiia levels were decreased when compared to the controls (Lu, Cheng & Shi, 2024). Industry Impact and Potential: Skincare product formulations designed to manage inflammation and support the skin barrier and microbiota diversity are emerging. These advanced formulas often include prebiotics, which can stimulate or inhibit bacterial growth (Seite & Misery, 2018). Specifically, new moisturiser formulations that include prebiotic ingredients that act directly on the skin microbiota are promising. This is because bacterial growth is sensitive to free water, and while traditional moisturisers improve surface hydration by binding water to skin cells, they do not increase free water levels. Non-pathogenic bacterial extracts may also be added to effectively support skin health by modulating the microbiota and reducing inflammation (Seite & Misery, 2018). Our Solution: Sequential offers comprehensive services to evaluate product impacts and formulations, leveraging a vast database of over 20,000 microbiome samples and 4,000 ingredients, and a global network of over 10,000 testing participants. Our team of experts will help your business develop innovative skincare solutions for sensitive skin that work with the microbiome to achieve optimal skin health. References: Lu, Y.-N., Cheng, L. & Shi, X.-M. (2024) Correlation between the facial skin microbiome and sensitive skin using the 2bRAD-M technique. International Journal of Cosmetic Science. doi:10.1111/ics.12941. Seite, S. & Misery, L. (2018) Skin sensitivity and skin microbiota: Is there a link? Experimental Dermatology. 27 (9), 1061–1064. doi:10.1111/exd.13686.
- Unlocking the Power of Rosemary Oil: Is This A Natural Solution for Scalp Health?
Rosemary oil has become increasingly popular in the hair care cosmetics industry, praised for its potential to improve scalp health and promote hair growth. Subsequent research has focused on examining the impact of rosemary oil products on the scalp microbiome and the treatment of various scalp conditions. What We Know: Rosmarinus officinalis, commonly known as rosemary, is a familiar aromatic household plant characterised by needle-like leaves. This medicinal plant is also renowned for its various beneficial properties, including cardiovascular health, nervous disorders treatment and notably, benefits for hair and scalp health through its ability to enhance microcapillary perfusion (Begum et al., 2023). Rosemary is also known to possess anti-inflammatory properties due to its rich content of phenolic phytoconstituents (Hashem et al., 2024). Moreover, the chemical composition of the plant encompasses essential oils containing primary constituents such as camphene, camphor, cineol and borneol. Additionally, it is known to harbour abundant flavonoids, bitter principles, tannins and terpenoids, alongside amino acids, steroids, glycosides, volatile oils and vitamins (Begum et al., 2023). Industry Impact and Potential: A study found that rosemary oil was as clinically effective as 2% minoxidil for treating androgenetic alopecia. Additionally, participants using rosemary oil experienced less scalp itching compared to those using minoxidil (Panahi et al., 2015). Hair lotion with 1% methanolic extract of R. officinalis administered in a study on mice demonstrated significant hair growth promoting activity, when compared to the control of 2% minoxidil hair lotion (Begum et al., 2023). An additional study combined rosemary with neem (Azadirachta indica) to create hair gel and leave-in products to treat dandruff. The products were successful, proving more effective than ketoconazole (a conventional antifungal agent) at managing Malassezia furfur, a dandruff-causing fungus, and Trichophyton rubrum, which is also associated with scalp disorders. Their products showed strong anti-inflammatory activity and also proved more effective than minoxidil in promoting hair growth (Hashem et al., 2024). Research like this suggests the potential of medicinal herbs like rosemary as natural and cost-effective ingredients to explore for targeting the scalp microbiome to treat diverse scalp conditions, thereby enhancing overall scalp and hair health (Hashem et al., 2024). Our Solution: With a database of 20,000 microbiome samples and 4,000 ingredients and a global network of 10,000 testing participants, Sequential provides tailored solutions for custom microbiome studies and product formulation. Considering rosemary oil-based scalp health products, our commitment to creating microbiome-safe and friendly formulations ensures the preservation of biome integrity. References: Begum, A., S, S., N, A.K. & Ali, S.S. (2023) Evaluation of Herbal Hair Lotion loaded with Rosemary for Possible Hair Growth in C57BL/6 Mice. Advanced Biomedical Research. 12, 60. doi:10.4103/abr.abr_306_21. Hashem, M.M., Attia, D., Hashem, Y.A., Hendy, M.S., AbdelBasset, S., Adel, F. & Salama, M.M. (2024) Rosemary and neem: an insight into their combined anti-dandruff and anti-hair loss efficacy. Scientific Reports. 14 (1), 7780. doi:10.1038/s41598-024-57838-w. Panahi, Y., Taghizadeh, M., Marzony, E.T. & Sahebkar, A. (2015) Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed. 13 (1), 15–21.











